# Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

> **NCT07309952** · PHASE2 · RECRUITING · sponsor: **Yang Hong** · enrollment: 28 (estimated)

## Conditions studied

- Locally Advanced Non-Small Cell Lung Cancer
- Stage IIIb Non-small Cell Lung Cancer
- Stage IIIC Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin (AUC 5)
- **DRUG:** Pemetrexed 500 mg/m2
- **RADIATION:** Stereotactic body radiotherapy (SBRT)
- **PROCEDURE:** non-small cell lung cancer

## Key facts

- **NCT ID:** NCT07309952
- **Lead sponsor:** Yang Hong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-10-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07309952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07309952, "Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07309952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*